ATE227987T1 - Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes - Google Patents

Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes

Info

Publication number
ATE227987T1
ATE227987T1 AT91912311T AT91912311T ATE227987T1 AT E227987 T1 ATE227987 T1 AT E227987T1 AT 91912311 T AT91912311 T AT 91912311T AT 91912311 T AT91912311 T AT 91912311T AT E227987 T1 ATE227987 T1 AT E227987T1
Authority
AT
Austria
Prior art keywords
treatment
receptor complex
glycine
nmda receptor
functional antagonists
Prior art date
Application number
AT91912311T
Other languages
English (en)
Inventor
Ramon Trullas
Phil Skolnick
Original Assignee
Us Secretary United States Dep
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Secretary United States Dep filed Critical Us Secretary United States Dep
Application granted granted Critical
Publication of ATE227987T1 publication Critical patent/ATE227987T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT91912311T 1990-06-18 1991-06-11 Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes ATE227987T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/541,032 US5086072A (en) 1990-06-18 1990-06-18 Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
PCT/US1991/003972 WO1991019493A1 (en) 1990-06-18 1991-06-11 Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex

Publications (1)

Publication Number Publication Date
ATE227987T1 true ATE227987T1 (de) 2002-12-15

Family

ID=24157917

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91912311T ATE227987T1 (de) 1990-06-18 1991-06-11 Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes

Country Status (8)

Country Link
US (1) US5086072A (de)
EP (1) EP0533832B1 (de)
JP (1) JP2609968B2 (de)
AT (1) ATE227987T1 (de)
AU (1) AU651125B2 (de)
CA (1) CA2085135C (de)
DE (1) DE69133156T2 (de)
WO (1) WO1991019493A1 (de)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
WO1997020552A1 (en) * 1995-12-07 1997-06-12 Albert Einstein College Of Medicine Of Yeshiva University Treatment of negative and cognitive symptoms of schizophrenia with glycine and its precursors
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
WO1998003189A1 (en) 1996-07-22 1998-01-29 Cognetix, Inc. Use of conantokins
US6391922B1 (en) 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
US20060167114A1 (en) * 1998-03-09 2006-07-27 Louis Shuster Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US6242456B1 (en) * 1998-03-09 2001-06-05 Trustees Of Tufts College Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
US20070197651A1 (en) * 1998-03-09 2007-08-23 Tufts University Treatment of stereotypic, self-injurious and compulsive behaviors in man and animals using antagonists of NMDA receptors
PT1073432E (pt) * 1998-04-14 2007-10-22 Gen Hospital Corp Utilização da d-alanina ou da d-serina para o tratamento da esquizofrenia
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
JP2002140219A (ja) * 2000-11-01 2002-05-17 Toshiba Corp ファイル処理方法、ファイル処理装置、ファイル管理用記録媒体
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
EP1383465B1 (de) * 2001-03-29 2011-08-10 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
EP1389181A4 (de) * 2001-04-02 2005-10-19 Panorama Res Inc Nitroxid- und nitron-antioxidationsmittel als therapeutika
WO2005000216A2 (en) 2003-05-27 2005-01-06 Forest Laboratories, Inc. Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
US7544478B2 (en) * 2003-08-08 2009-06-09 The Burnham Institute Method for screening for compounds that modulate P16 mediated regulation of NMDA receptors
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
JP2007517049A (ja) * 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
PL1874282T3 (pl) 2005-04-06 2011-04-29 Adamas Pharmaceuticals Inc Sposoby i kompozycje do leczenia zaburzeń OUN
US7531572B2 (en) * 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
ES2553968T3 (es) 2008-09-18 2015-12-15 Northwestern University Moduladores del receptor NMDA y sus usos
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP3132793A1 (de) 2009-12-02 2017-02-22 Adamas Pharmaceuticals, Inc. Amantadinzusammensetzungen und verfahren zur verwendung
MX2012009388A (es) 2010-02-11 2012-10-01 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato estabilizado de estructura secundaria y sus usos.
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP2012158527A (ja) * 2011-01-31 2012-08-23 Mitsubishi Gas Chemical Co Inc うつ予防
PT2931291T (pt) 2012-12-11 2021-12-03 Mclean Hospital Corp Tratamento com xénon como complemento da psicoterapia para perturbações psiquiátricas
WO2014116739A1 (en) 2013-01-22 2014-07-31 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses l-4-chlorokynurenine
CN105229010A (zh) 2013-01-29 2016-01-06 阿普廷伊克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2015009772A (es) 2013-01-29 2016-05-31 Aptinyx Inc Moduladores de receptores nmda de espiro-lactama y sus usos.
CN105026401A (zh) 2013-01-29 2015-11-04 诺雷克斯股份有限公司 螺-内酰胺nmda受体调节剂及其用途
KR102280616B1 (ko) 2013-01-29 2021-07-21 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
CA3024606C (en) 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
CN109661398B (zh) 2016-08-01 2022-07-05 阿普廷伊克斯股份有限公司 螺-内酰胺和二-螺-内酰胺nmda受体调节剂及其用途
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
SG11201900558RA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2020008107A (es) 2018-01-31 2020-09-25 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos.
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE882361R (fr) * 1980-03-21 1980-09-22 Merck & Co Inc PROCEDE DE PREPARATION DE 10,11-DIHYDRO-5H-DIBENZO (a,d) CYCLOHEPTENE-5,10-IMINES SUBSTITUEES EN POSITION 5
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
GB8703749D0 (en) * 1987-02-18 1987-03-25 Sandoz Ltd Piperazinecarboxylic acid
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents

Also Published As

Publication number Publication date
CA2085135C (en) 1997-02-25
US5086072A (en) 1992-02-04
DE69133156T2 (de) 2003-03-27
AU651125B2 (en) 1994-07-14
DE69133156D1 (de) 2003-01-02
CA2085135A1 (en) 1991-12-19
JP2609968B2 (ja) 1997-05-14
EP0533832B1 (de) 2002-11-20
JPH06501454A (ja) 1994-02-17
EP0533832A1 (de) 1993-03-31
WO1991019493A1 (en) 1991-12-26
EP0533832A4 (en) 1993-04-28
AU8208491A (en) 1992-01-07

Similar Documents

Publication Publication Date Title
ATE227987T1 (de) Behandlung von gemütskrankheiten mit funktionellen antagonisten des glycin/nmda- rezeptorkomplexes
LU91271I2 (fr) Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69129302D1 (de) Inhibitoren des tumorwachstums aus geweben, methoden ihrer herstellung und verwendungen
DE69329503D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
DE69532482D1 (de) Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
DK0473671T3 (da) Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
NZ299859A (en) Oxazolidine and morpholine derivatives; medicaments for treatment of central nervous system diseases
ATE236654T1 (de) Therapeutische kombinationen von rar-antagonisten und rxr-agonisten
EA200200194A1 (ru) Антагонисты хемокинного рецептора и способы их применения
FI960727A (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
EA199700116A1 (ru) Трициклические бензазепины как антагонисты вазопрессина, способ их получения, фармкомпозиция на их основе и способ лечения
NO944578L (no) Eksitatoriske aminosyre reseptor antagonister
EA199700111A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина
EA200300716A1 (ru) Гетероциклилалкилиндольные или -азаиндольные соединения в качестве лиганд 5-гидрокситриптамина-6
ATE185969T1 (de) Potenzierung von nmda-antagonisten
EA200000693A1 (ru) Антагонисты хемокинного рецептора и способы их применения
AU655958B2 (en) Use of quisqualate-receptor antagonists for treating Parkinson's disease
IL117157A (en) Preparation of factor ix form biological sources
ES2062762T3 (es) Metodo para tratar el choque septico.
ATE167398T1 (de) Behandlungsverfahren für therapiewiderstehende schizophrenie mit amperozide
MY106163A (en) Bcrf1 antagonists for treating epstein-barr virus infections.
EA200101043A1 (ru) Способ лечения неврологических или нейропсихиатрических расстройств
ES8300477A1 (es) Procedimiento para la preparacion de una composicion para el tratamiento del cancer
ES1021390U (es) Plantilla terapeutica perfeccionada.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties